Pharma BD Deal Intelligence

SpringWorks Therapeutics, Inc. / Rappta Therapeutics Oy

2025 · Licensing/Option · Complete

Rappta Therapeutics announced an exclusive global license agreement with SpringWorks Therapeutics on January 13, 2025 for RPT04402, a first-in-class molecular glue targeting specific PP2A complexes, initially for a molecularly defined subset of uterine cancers. SpringWorks paid $13 million upfront and is responsible for global development and commercialization; Rappta is eligible for undisclosed clinical, regulatory and commercial milestones and tiered single-digit royalties. SpringWorks expected to file an IND by the end of 2025. Total deal value left NULL because milestone amounts were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals